The Hippo Pathway in Prostate Cancer
AbstractDespite recent efforts, prostate cancer (PCa) remains one of the most common cancers in men. Currently, there is no effective treatment for castration-resistant prostate cancer (CRPC). There is, therefore, an urgent need to identify new therapeutic targets. The Hippo pathway and its downstream effectors—the transcriptional co-activators, Yes-associated protein (YAP) and its paralog, transcriptional co-activator with PDZ-binding motif (TAZ)—are foremost regulators of stem cells and cancer biology. Defective Hippo pathway signaling and YAP/TAZ hyperactivation are common across various cancers. Here, we draw on insights learned from other types of cancers and review the latest advances linking the Hippo pathway and YAP/TAZ to PCa onset and progression. We examine the regulatory interaction between Hippo-YAP/TAZ and the androgen receptor (AR), as main regulators of PCa development, and how uncontrolled expression of YAP/TAZ drives castration resistance by inducing cellular stemness. Finally, we survey the potential therapeutic targeting of the Hippo pathway and YAP/TAZ to overcome PCa. View Full-Text
Share & Cite This Article
Salem, O.; Hansen, C.G. The Hippo Pathway in Prostate Cancer. Cells 2019, 8, 370.
Salem O, Hansen CG. The Hippo Pathway in Prostate Cancer. Cells. 2019; 8(4):370.Chicago/Turabian Style
Salem, Omar; Hansen, Carsten G. 2019. "The Hippo Pathway in Prostate Cancer." Cells 8, no. 4: 370.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.